GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Travere Therapeutics
Travere Therapeutics specializes in treating rare kidney diseases. Its stock price reflects the commercial success of its drugs and the results of clinical trials of new drugs. The chart highlights both scientific breakthroughs and the high risks inherent in the biotech sector.
Share prices of companies in the market segment - Pharma kidney
Travere is a biopharmaceutical company specializing in the treatment of rare kidney diseases. Its business consists of this segment alone. We classify it as part of the Pharma kidney sector, and the chart below shows the general dynamics of biotech companies, where value is determined by the success of clinical data.
Broad Market Index - GURU.Markets
Travere Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, particularly kidney disease. Its focus on orphan diseases makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Travere compares to it.
Change in the price of a company, segment, and market as a whole per day
TVTX - Daily change in the company's share price Travere Therapeutics
Shares of Travere Therapeutics, which fights rare kidney diseases, are highly sensitive to news. change_co measures daily volatility driven by clinical trial data. This metric is fundamental to building complex biotech risk assessment models on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma kidney
Travere Therapeutics, Inc. is a biopharmaceutical company. This chart highlights the sector's extreme volatility. Comparison with TVTX, which focuses on rare diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Travere Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of rare kidney diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Travere's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Travere Therapeutics
Travere is a biopharmaceutical company specializing in the treatment of kidney diseases. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant component of the overall "noise" and dynamics of the stock market.
Annual dynamics of market capitalization of the market segment - Pharma kidney
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare kidney diseases. The chart shows how its success in bringing drugs to market and clinical trial results impacts its performance relative to the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Travere Therapeutics, which specializes in drugs for rare diseases, operates in a non-cyclical sector. Demand for its drugs is unaffected by the economic climate. The company's share price performance is driven by its success in research and commercialization, making it a growth story isolated from general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Travere Therapeutics
Travere, a biopharmaceutical company specializing in rare kidney diseases. The monthly fluctuations on the chart reflect the commercial success of its approved drugs and news about clinical trials of new developments.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Biopharmaceutical companies targeting rare diseases, such as kidney disease, represent a niche but important segment. The dynamics of this sector, reflected in the chart, illustrate how investors evaluate the potential of orphan drug treatments. This provides context for companies like Travere Therapeutics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Travere Therapeutics specializes in treating rare kidney diseases. The company's shares operate in the biotech world, where clinical trial data and regulatory decisions are the primary drivers. Their performance is largely unrelated to overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Travere Therapeutics
Travere Therapeutics specializes in treating rare kidney diseases. Its weekly stock price is dependent on FDA decisions, clinical trial data, and sales reports for its approved drugs. This is a high-risk but potentially highly profitable segment of the pharmaceutical industry.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Travere, as a biopharmaceutical company focused on rare diseases, is driven by its own unique news, not by general trends. FDA decisions on its drugs are its main driver. The chart clearly shows how these events trigger sharp movements, completely disconnected from the dynamics of the broader pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Travere Therapeutics specializes in treating rare kidney diseases. Shares of companies like this one are driven by news of drug approvals and trial results. The chart will show how independent its unique path is from overall market sentiment.
Market capitalization of the company, segment and market as a whole
TVTX - Market capitalization of the company Travere Therapeutics
Travere Therapeutics' market capitalization reflects its focus on treating rare kidney diseases. Its price chart shows how investors react to regulatory decisions and clinical trial data for its drugs. The company's valuation is a bet on its ability to capture a significant niche in a market with a high unmet need.
TVTX - Share of the company's market capitalization Travere Therapeutics within the market segment - Pharma kidney
Travere Therapeutics specializes in treating rare diseases, particularly in nephrology. Its market share reflects its pipeline of approved drugs and developments targeting patients with limited treatment options.
Market capitalization of the market segment - Pharma kidney
Here's a chart showing the biotech sector's market capitalization. Travere Therapeutics specializes in treating rare diseases, particularly kidney disease. This market has significant potential, as many of these conditions lack effective treatment. Travere strives to bring hope to these patients by bringing new drugs to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Travere Therapeutics specializes in developing drugs to treat rare diseases, particularly kidney disease. Its market capitalization represents hope for patients with orphan diseases. The chart below shows the share price of biotech companies solving complex medical problems.
Book value capitalization of the company, segment and market as a whole
TVTX - Book value capitalization of the company Travere Therapeutics
Travere Therapeutics' book value is its equity and intellectual property, which are focused on treating rare kidney diseases. The chart tells the story of a biotech company launching its first drugs, a critical moment when years of R&D investment begin to translate into commercial assets and revenue.
TVTX - Share of the company's book capitalization Travere Therapeutics within the market segment - Pharma kidney
Travere Therapeutics focuses on treating rare kidney diseases. The chart shows its share of actual R&D assets. These are its research laboratories where drugs designed to slow the progression of serious diseases are developed and tested.
Market segment balance sheet capitalization - Pharma kidney
Travere Therapeutics is a biopharmaceutical company focused on rare diseases. Its model is moderately capital-intensive, as in addition to R&D, it has a commercial infrastructure for approved drugs. Compared to the biotech sector, it is heavier than pure R&D companies but lighter than the giants.
Book value of all companies included in the broad market index - GURU.Markets
Travere Therapeutics' assets represent hope for patients with rare kidney diseases. The company's balance sheet reflects the value of its pipeline of approved and developing drugs. This chart shows the capital behind a company focused on solving complex medical problems neglected by major players.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Travere Therapeutics
Travere Therapeutics specializes in drugs for rare kidney diseases. Its market value is a measure of its intellectual property and the commercial potential of its approved and developing drugs. The gap with its book value in the chart shows how much investors believe in the success of its niche strategy.
Market to book capitalization ratio in a market segment - Pharma kidney
Travere Therapeutics specializes in rare kidney diseases. Its value is determined by the potential of its drugs, which target niche markets. This chart shows the premium investors pay for exclusivity and the hope of drug approval, which is not tied to the company's tangible assets.
Market to book capitalization ratio for the market as a whole
Travere Therapeutics specializes in treating rare kidney diseases. The company's market capitalization is based on the potential of its approved drugs and those in development. This chart shows how the market values this niche pharmaceutical company, whose value lies in its intellectual property rather than its tangible assets.
Debts of the company, segment and market as a whole
TVTX - Company debts Travere Therapeutics
Travere Therapeutics specializes in developing treatments for rare kidney diseases. The path from research to commercialization is long and expensive. Debt financing is an important tool allowing the company to support its clinical programs and prepare for the commercialization of life-saving drugs for patients.
Market segment debts - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in rare kidney diseases. After new drugs are approved, the focus shifts to commercialization. This chart shows how the company funds its marketing efforts and further research, using sales revenue and managing its financial structure to ensure long-term growth.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Travere Therapeutics
Travere Therapeutics specializes in developing drugs to treat rare kidney diseases. This chart shows the biotech company's financial position at the commercialization stage. Capital is used here to market and sell its approved drugs, as well as to fund further research to expand their use.
Market segment debt to market segment book capitalization - Pharma kidney
Travere Therapeutics specializes in treating rare kidney diseases. The chart shows the overall debt burden in a sector where developing orphan drugs requires significant and long-term investments. It allows one to assess how Travere's financial strategy for raising research funds aligns with industry standards in this complex niche.
Debt to book value of all companies in the market
Travere Therapeutics operates in the rare disease niche. The chart shows the overall debt burden across the market. It helps understand the extent to which the company's business model, focused on orphan drugs, allows it to pursue its own financial strategy, independent of overall macroeconomic and credit cycles.
P/E of the company, segment and market as a whole
P/E - Travere Therapeutics
This chart for Travere Therapeutics, which focuses on treating rare kidney diseases, assesses its ability to carve out a niche. Following drug approval, the price-to-earnings ratio reflects investor expectations for sales volumes. The price-to-earnings ratio reflects the market's reaction to revenue reports and news of drug expansion.
P/E of the market segment - Pharma kidney
This chart reflects the average valuation for the rare disease-focused biopharmaceutical sector—the benchmark for Travere. Comparing the company's valuation of already approved drugs with the industry average helps understand how optimistic the market is about their commercial potential and future developments.
P/E of the market as a whole
Travere Therapeutics specializes in drugs for rare kidney diseases, a niche market with high unmet demand. This chart, which shows overall investor risk appetite in biotech, is important for Travere. It determines how easily the company can raise capital for expensive research and bring its life-saving drugs to market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Travere Therapeutics
Travere Therapeutics specializes in developing drugs for rare diseases, particularly kidney diseases. The company's future depends on the commercial success of its approved drugs and the results of clinical trials. This chart reflects analyst expectations for sales volumes and the potential of its scientific developments to become new treatment standards.
%20P%2FE%20Travere%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Travere-Therapeutics&v=1772656919075 "Chart of the company's future (projected) P/E Travere Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
Travere Therapeutics specializes in treating rare kidney, immune, and metabolic diseases. Its valuation relative to other biotech companies reflects investor expectations for its pipeline. A high valuation may indicate confidence in the commercial success of currently approved drugs and the potential for future developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772656919089 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Travere Therapeutics specializes in developing drugs to treat rare kidney diseases. The company's future depends on the success of its clinical programs and regulatory approvals. This chart reflects the overall risk appetite of investors. For niche biotechs working with rare diseases, a positive market environment facilitates capital raising and supports the company's valuation.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772656919100 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Travere Therapeutics
Travere Therapeutics specializes in developing and commercializing treatments for rare diseases, particularly kidney disease. The financial results illustrated in this chart depend on the successful launch of its drugs. Regulatory approvals and acceptance by the medical community are key to its growth.
Profit of companies in the market segment - Pharma kidney
Travere Therapeutics specializes in treating rare kidney diseases, offering hope to patients with limited treatment options. This chart shows the combined profitability of companies operating in nephrology. It helps investors understand whether this narrow and complex pharmaceutical field is commercially viable and promising.
Overall market profit
Travere Therapeutics specializes in treating rare kidney diseases. It is a highly specialized biopharmaceutical company whose value is determined by the progress of its drug development and commercialization. Macroeconomic cycles, as shown by this chart, have virtually no impact on patient demand for treatment, making TVTX's business independent of them.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Travere Therapeutics
Travere Therapeutics specializes in the development and commercialization of treatments for rare kidney diseases. The company's future profitability depends on the successful launch of its drugs and their acceptance by the medical community. This chart shows analysts' confidence in the commercial potential of the company's portfolio in this complex and specialized area of medicine.
%20profit%20of%20the%20company%20Travere%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Travere-Therapeutics&v=1772656919109 "Graph of future (projected) profit of the company Travere Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases, particularly kidney disease. This chart shows revenue projections for its segment. It helps investors assess the growth potential in the orphan disease niche, where drug prices are high but development risks are also high.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772656919115 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
Travere Therapeutics specializes in treating rare kidney diseases. The overall economic climate, reflected in this chart, influences healthcare sector funding. Stable economic growth drives investment in biotechnology and allows healthcare systems to afford the high-cost rare disease drugs developed by Travere.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772656919119 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Travere Therapeutics
Travere Therapeutics specializes in treating rare kidney diseases. This chart shows how investors value the current sales of its approved drugs and the potential revenue from products in development, placing bets on its leadership in this narrow but important niche.
P/S market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare kidney diseases. This chart shows the average valuation in the pharmaceutical sector. It reflects investor expectations for companies working to develop treatments for patients with limited or no treatment options, and their revenue potential.
P/S of the market as a whole
Travere Therapeutics specializes in the development and commercialization of drugs for rare diseases, particularly kidney disease. The company's revenue depends on the market success of its drugs. This chart helps investors understand the market premium for its focus on rare diseases compared to average revenue estimates for the pharmaceutical industry as a whole.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Travere Therapeutics
Travere Therapeutics specializes in treating rare diseases, particularly kidney disease. The company's future revenue depends on the commercial success of its drugs. This chart shows how the market perceives the potential sales of its orphan drug products, where prices are high and competition is limited.
%20P%2FS%20Travere%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Travere-Therapeutics&v=1772656919137 "The graph of the company's future (projected) P/S Travere Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
Travere Therapeutics specializes in developing and commercializing treatments for rare diseases, with a particular focus on kidney disease. Its success depends on the approval and adoption of its niche drugs. This chart shows how investors assess the commercial potential of its portfolio compared to other companies in the rare disease space.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772656919142 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
This indicator reflects market confidence in biotech companies targeting rare diseases. For Travere Therapeutics, which focuses on treating kidney diseases, it reflects the investment climate. Investor optimism allows it to attract funding for the development and commercialization of drugs for patients who previously had no treatment options.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772656919147 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company specializing in the development and delivery of treatments for rare diseases, particularly kidney disease. This chart shows the revenue from sales of its commercial products. Sales growth reflects successful patient identification and access to life-saving therapeutics.
Sales of companies in the market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare kidney diseases. This chart shows the size of the nephrology drug market. Travere strives to offer new treatments for patients with limited therapeutic options, and its developments are part of a global effort to combat chronic kidney disease.
Overall market sales
Travere Therapeutics specializes in treating rare kidney diseases. Like many biotech companies, its success depends on clinical trial results and regulatory approval. The overall economic climate, shown in this chart, influences the investment climate and investor willingness to finance long-term, risky projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company specializing in developing treatments for rare kidney diseases. Its future revenue depends on the successful commercialization of its currently approved drugs and the results of clinical trials for new ones. This chart shows analysts' forecasts for the market size of its drugs and the speed of their adoption by the medical community.
%20sales%20of%20the%20company%20Travere%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Travere-Therapeutics&v=1772656919209 "Schedule of future (projected) sales of the company Travere Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly kidney disease. The forecast reflects expectations for the nephrology pharmaceutical segment. It highlights the significant unmet demand for treatments for these conditions, creating an opportunity for Travere.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772656919257 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Travere Therapeutics is a biopharmaceutical company focused on treating rare diseases, particularly kidney disease. Its success depends on the approval and commercialization of its drugs. The overall economic situation, reflected in this chart, influences healthcare funding and the ability of insurers to cover the cost of expensive drugs for orphan diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772656919272 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Travere Therapeutics
Travere Therapeutics focuses on developing and marketing treatments for rare kidney diseases. This chart reflects the company's financial performance with commercialized products. Its profitability depends on sales volumes of these specialized drugs, while the company continues to actively invest in R&D to bring new therapies to market.
Market segment marginality - Pharma kidney
Travere Therapeutics specializes in developing and delivering treatments for rare diseases, particularly kidney disease. Profitability for such a company depends on the success of clinical trials and the pricing of unique drugs. This metric reflects its operating model and cost structure compared to other players in the rare disease niche.
Market marginality as a whole
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare kidney diseases. This overall profitability chart is not directly relevant to the company. The company's future success and profitability depend on clinical trial results, regulatory approval, and the ability to commercialize treatments for patients with limited treatment options.
Employees in the company, segment and market as a whole
Number of employees in the company Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company focused on treating rare kidney, liver, and metabolic diseases. The graph shows the team bringing new drugs to market. Headcount growth, particularly in the commercial team, is a key indicator of successful drug launches.
Share of the company's employees Travere Therapeutics within the market segment - Pharma kidney
Travere Therapeutics specializes in developing treatments for rare diseases, particularly kidney disease. This chart shows the percentage of leading nephrologists, scientists, and clinicians working in this narrow therapeutic area the company attracts. It reflects its concentration of unique expertise necessary for the development of life-saving medicines.
Number of employees in the market segment - Pharma kidney
Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing and delivering treatments for people with rare kidney diseases. Its mission is to provide therapies where they don't exist. This chart shows employment in the specialty kidney pharmaceutical industry, demonstrating how a focus on rare diseases is creating new, knowledge-intensive jobs.
Number of employees in the market as a whole
Travere Therapeutics specializes in treating rare diseases, particularly kidney disease. Their business is not dependent on broad economic trends, but is driven by scientific advances and patient needs. The growth of such companies demonstrates the diversification of the economy and the creation of high-tech jobs in a field where value is measured in lives saved.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Travere Therapeutics (TVTX)
Travere Therapeutics specializes in treating rare kidney diseases. This chart shows how the market values drugs for orphan diseases. The high market capitalization per employee reflects the significant price potential of these drugs and the value of the intellectual property created by a relatively small team.
%20of%20the%20company%20Travere%20Therapeutics%20(TVTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Travere-Therapeutics-TVTX&v=1772656919467 "Chart of market capitalization per employee (in thousands of dollars) of the company Travere Therapeutics (TVTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Travere Therapeutics (TVTX) is a biopharmaceutical company specializing in developing treatments for rare diseases, particularly kidney diseases (e.g., IgA nephropathy). This chart shows the average market capitalization per employee in the sector. It helps assess how the market values their R&D portfolio and the commercial potential of their niche drugs per scientist.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772656919476 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases, particularly kidney disease. This chart shows the average market value generated by one specialist. It illustrates the high valuation the market places on companies solving complex medical problems.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772656919481 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Travere Therapeutics (TVTX)
Travere Therapeutics specializes in treating rare kidney diseases. The company has approved drugs. This chart demonstrates how effectively their dedicated team (R&D and commercial) can market and sell drugs for specific patient groups at a high price, generating net profit.
%20Chart%20Travere%20Therapeutics%20(TVTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Travere-Therapeutics-TVTX&v=1772656919483 "Company Profit Per Employee (in thousands of dollars) Chart Travere Therapeutics (TVTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Travere (TVTX) is an R&D biotech company (rare kidney diseases). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (biotech) is high. This benchmark reflects a "one-hit wonder": the sector spends millions on R&D, and a single successful orphan drug recoups all costs.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772656919495 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Travere Therapeutics is a biopharmaceutical company specializing in rare diseases, primarily kidney disease. The company has approved drugs. This chart shows how profits from current sales (for example, Filspari) offset the enormous R&D costs in other areas. It's a balance between commercialization and future innovation.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772656919503 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Travere Therapeutics (TVTX)
Travere Therapeutics is a biopharmaceutical company specializing in rare kidney diseases. For a company working with orphan diseases, this chart demonstrates the effectiveness of a niche strategy. It reflects the ability to generate significant revenue by selling expensive drugs to a small number of patients.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Travere-Therapeutics-TVTX&v=1772656919504 "Sales chart per company employee Travere Therapeutics (TVTX)")
Sales per employee in the market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases, particularly kidney disease. This chart shows the average revenue per employee in this segment. It helps assess how productive Travere's R&D and commercialization team is in this highly specialized niche compared to its competitors.
Sales per employee for the market as a whole
Travere Therapeutics specializes in drugs for rare diseases, particularly kidney disease. The company is in the commercialization phase of its first products. This chart is key. It demonstrates how effectively their highly specialized sales and marketing team communicates the value of their drugs to doctors and patients.
Short shares by company, segment and market as a whole
Shares shorted by company Travere Therapeutics (TVTX)
Travere Therapeutics specializes in treating rare kidney diseases. Its drugs target niche markets but face intense competition and approval challenges. This chart shows how many investors doubt the company's drug commercialization or anticipate negative regulatory decisions.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Travere-Therapeutics-TVTX&v=1772656919510 "Short Shares Chart for the Company Travere Therapeutics (TVTX)")
Shares shorted by market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare kidney diseases. Their success depends on the approval and adoption of their targeted therapies. This chart shows the overall short position in the nephrology-focused biotech sector. Its growth signals high investor skepticism about the success of clinical trials in this challenging area of drug development.
Shares shorted by the overall market
Travere (TVTX) is a biotech focused on rare kidney diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk. Biotech stocks, even those with approved drugs, often sell off when general pessimism rules the market.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Travere Therapeutics (TVTX)
Travere Therapeutics focuses on rare kidney diseases. Biotech stocks are extremely sensitive to trial news. This chart measures the strength and speed of price movements following such news. It helps assess whether investor enthusiasm for a new drug is excessive (overbought) or disappointment from a failure is too strong (oversold).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Travere-Therapeutics-TVTX&v=1772656919526 "RSI 14 indicator chart for the company's stock Travere Therapeutics (TVTX)")
RSI 14 Market Segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company focused on treating rare (orphan) diseases, with a particular focus on kidney disease. Their success hinges on the approval of drugs like Filspari. This chart measures the overall momentum in the niche biopharma sector. It helps assess whether the entire segment is overheated against general expectations, or whether Travere's performance is unique.
RSI 14 for the overall market
Travere Therapeutics (TVTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TVTX (Travere Therapeutics)
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare diseases, with a particular focus on kidney diseases (e.g., IgA nephropathy). This chart shows the average target price analysts predict based on the commercial potential of its approved drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TVTX-Travere-Therapeutics&v=1772656919540 "A chart showing analyst consensus forecasts for the expected stock price. TVTX (Travere Therapeutics)")
The difference between the consensus estimate and the actual stock price TVTX (Travere Therapeutics)
Travere Therapeutics (TVTX) is a biopharmaceutical company focused on treating rare kidney diseases. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting analysts' confidence in the commercial success of their drugs for nephropathy and other rare kidney diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TVTX-Travere-Therapeutics&v=1772656919540 "A chart showing the difference between the consensus forecast and the actual stock price. TVTX (Travere Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Travere Therapeutics is a biopharmaceutical company specializing in the treatment of rare kidney diseases. Its flagship drug, Filspari, is approved for the treatment of IgA nephropathy. This chart shows overall expectations for the kidney pharmaceutical sector. It reflects whether experts believe in the commercial potential of new nephrology drugs.
Analysts' consensus forecast for the overall market share price
Travere Therapeutics (TVTX) is a biotech company focused on treating rare kidney diseases. This chart of overall market sentiment is important. Optimism = the market is willing to fund R&D. But TVTX has a product, so during a recession (pessimism), investors may appreciate the non-cyclical nature of treatment demand.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Travere Therapeutics
Travere Therapeutics is a biotech company specializing in rare diseases, with a particular focus on kidney disease. Their strategy is to achieve accelerated approvals for drugs in high-need niches. This chart evaluates their kidney drug pipeline, reflecting their commercial launches and clinical trial progress.
AKIMA Market Segment Index - Pharma kidney
Travere Therapeutics (TVTX) is a biotech focused on rare diseases, particularly kidney disease; the company has received approval for a drug (Filspari) for the treatment of IgA nephropathy. This summary metric evaluates R&D. The graph shows the segment average. This benchmark provides insight into how Travere's niche (rare kidney) R&D focus differentiates it from the average pharma company.
The AKIM Index for the overall market
Travere is a biotech company working on a treatment for rare kidney diseases. Its goal is to save patients from dialysis. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this growth and commercialization story in the "defensive" sector compares to the broader economic trends that influence investor risk appetite.
